Skip to main content
Caplight Logo









Autolomous

Autolomous

Private
LondonHealthcare & Life Scienceshttps://autolomous.com/

Last Round

Grant

Jun 12, 2023

Total Funding Raised

$2.13M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Autolomous is a software company that provides a digital manufacturing management platform for cell and gene therapy developers and manufacturers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Quality Management, Workflow Automation, Compliance

Business Model

B2B

Customer Profile

Subscription SaaS, Freemium

AI Layer

Application

Keywords

manufacturing execution systemMESadvanced therapy medicinal productsATMPelectronic batch recordseBRcell and gene therapyquality management systemQMSbiotech manufacturingpharma supply chaindigital manufacturingcGMP compliancelab informaticsbioprocessing softwarepharma tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autolomous Comparables

Compare Autolomous with similar companies based on industry and business-model similarity.

Autolomous comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TrakCel
86%
Leucine
78%
Apprentice
78%

Autolomous Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 12, 2023
Early FundingDec 27, 2022
GrantJul 27, 2021
DebtMay 4, 2021
SeedAug 5, 2020

Key People

Founding team and executive leadership

Alexander Seyf

Chief Executive Officer

Executive Team

Alexis Blain

Chief Technology Officer

Executive Team

Walid Fahme

Chief Operating Officer

Executive Team

Autolomous Investors

Notable investors and investment history

Autolomous investors
InvestorRounds
UKRI Innovate UKDebt, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Grew 18% QoQ, from 34 to 40 employees.

  • May 14, 2026

    Monthly visitors increased 86% MoM, reaching 4K.

Recent news

Latest coverage and updates

  • integrates_withJul 8, 2026

    Autolomous integrated with Cellular Origins Ltd on Jul 8th '26.

Autolomous Filings

Explore SEC and related filing metadata, where available.

Autolomous filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Autolomous's valuation, stock price, and market status.

Is Autolomous a public or private company?

Autolomous is a private company.

What is the current stock price of Autolomous?

Autolomous is a private company with no public stock price. No recent secondary market data is available.

How much is Autolomous worth (valuation)?

Valuation information for Autolomous is not publicly available.

Can I buy Autolomous stock?

Autolomous shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Autolomous's last funding round?

Autolomous's most recent funding round was Grant on June 12, 2023.

Who are the main investors in Autolomous?

Key investors in Autolomous include UKRI Innovate UK.

Will Autolomous IPO soon?

No public IPO plans have been announced for Autolomous.

How can I track Autolomous secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Autolomous's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range32
Year Founded2019
Last FundingJun 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?